share_log

These 4 Measures Indicate That Winning Health Technology Group (SZSE:300253) Is Using Debt Reasonably Well

These 4 Measures Indicate That Winning Health Technology Group (SZSE:300253) Is Using Debt Reasonably Well

這4項指標表明,Winning Health Technology Group(深圳證券交易所代碼:300253)的債務使用情況相當不錯
Simply Wall St ·  01/05 17:04

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility of prices, but whether you will suffer a permanent loss of capital.' It's only natural to consider a company's balance sheet when you examine how risky it is, since debt is often involved when a business collapses. Importantly, Winning Health Technology Group Co., Ltd. (SZSE:300253) does carry debt. But the real question is whether this debt is making the company risky.

傳奇基金經理李露(由查理·芒格支持)曾經說過:“最大的投資風險不是價格的波動,而是你是否會遭受永久的資本損失。”當你檢查公司的資產負債表的風險時,考慮它的資產負債表是很自然的,因爲企業倒閉時通常會涉及債務。重要的是,威寧健康科技集團有限公司(深圳證券交易所代碼:300253)確實有債務。但真正的問題是這筆債務是否使公司面臨風險。

What Risk Does Debt Bring?

債務會帶來什麼風險?

Debt assists a business until the business has trouble paying it off, either with new capital or with free cash flow. If things get really bad, the lenders can take control of the business. However, a more usual (but still expensive) situation is where a company must dilute shareholders at a cheap share price simply to get debt under control. Of course, plenty of companies use debt to fund growth, without any negative consequences. The first thing to do when considering how much debt a business uses is to look at its cash and debt together.

債務可以幫助企業,直到企業難以償還債務,無論是新資本還是自由現金流。如果情況變得非常糟糕,貸款人可以控制業務。但是,更常見(但仍然昂貴)的情況是,公司爲了控制債務,必須以低廉的股價稀釋股東。當然,許多公司使用債務爲增長提供資金,而不會產生任何負面影響。在考慮企業使用多少債務時,要做的第一件事是同時考慮其現金和債務。

See our latest analysis for Winning Health Technology Group

查看我們對Winning Health科技集團的最新分析

How Much Debt Does Winning Health Technology Group Carry?

威寧健康科技集團揹負了多少債務?

The image below, which you can click on for greater detail, shows that at September 2023 Winning Health Technology Group had debt of CN¥1.04b, up from CN¥983.7m in one year. However, it also had CN¥752.9m in cash, and so its net debt is CN¥288.1m.

您可以點擊下圖查看更多詳情,該圖片顯示,截至2023年9月,Winning Health Technology Group的債務爲10.4億元人民幣,高於一年的9.837億元人民幣。但是,它也有7.529億元的現金,因此其淨負債爲2.881億元人民幣。

debt-equity-history-analysis
SZSE:300253 Debt to Equity History January 5th 2024
SZSE: 300253 2024 年 1 月 5 日債務與股本比率的歷史記錄

How Healthy Is Winning Health Technology Group's Balance Sheet?

威寧健康科技集團的資產負債表有多健康?

We can see from the most recent balance sheet that Winning Health Technology Group had liabilities of CN¥1.45b falling due within a year, and liabilities of CN¥1.15b due beyond that. On the other hand, it had cash of CN¥752.9m and CN¥3.20b worth of receivables due within a year. So it can boast CN¥1.35b more liquid assets than total liabilities.

我們可以從最新的資產負債表中看出,Winning Health Technology Group的負債爲14.5億元人民幣,一年後到期的負債爲11.5億元人民幣。另一方面,它有7.529億元的現金和價值32.0億元人民幣的應收賬款將在一年內到期。因此,它擁有的流動資產可以多出13.5億元人民幣 負債。

This surplus suggests that Winning Health Technology Group has a conservative balance sheet, and could probably eliminate its debt without much difficulty.

這種盈餘表明,Winning Health Technology Group的資產負債表比較保守,可以毫不費力地消除債務。

We use two main ratios to inform us about debt levels relative to earnings. The first is net debt divided by earnings before interest, tax, depreciation, and amortization (EBITDA), while the second is how many times its earnings before interest and tax (EBIT) covers its interest expense (or its interest cover, for short). This way, we consider both the absolute quantum of the debt, as well as the interest rates paid on it.

我們使用兩個主要比率來告知我們相對於收益的債務水平。第一個是淨負債除以利息、稅項、折舊和攤銷前的收益(EBITDA),第二個是其利息和稅前收益(EBIT)覆蓋其利息支出(或簡稱利息保障)的多少倍。這樣,我們既考慮債務的絕對數量,也考慮爲債務支付的利率。

Winning Health Technology Group's net debt is sitting at a very reasonable 1.7 times its EBITDA, while its EBIT covered its interest expense just 5.8 times last year. While these numbers do not alarm us, it's worth noting that the cost of the company's debt is having a real impact. Importantly Winning Health Technology Group's EBIT was essentially flat over the last twelve months. Ideally it can diminish its debt load by kick-starting earnings growth. When analysing debt levels, the balance sheet is the obvious place to start. But it is future earnings, more than anything, that will determine Winning Health Technology Group's ability to maintain a healthy balance sheet going forward. So if you're focused on the future you can check out this free report showing analyst profit forecasts.

Winning Health Technology Group的淨負債相當合理,爲其息稅折舊攤銷前利潤的1.7倍,而去年其息稅前利潤僅爲利息支出的5.8倍。儘管這些數字並沒有使我們感到震驚,但值得注意的是,公司的債務成本正在產生實際影響。重要的是,Winning Health Technology Group的息稅前利潤在過去十二個月中基本持平理想情況下,它可以通過啓動收益增長來減少債務負擔。在分析債務水平時,資產負債表是顯而易見的起點。但是,未來的收益將決定Winning Health Technology Group未來維持健康資產負債表的能力。因此,如果您專注於未來,可以查看這份顯示分析師利潤預測的免費報告。

But our final consideration is also important, because a company cannot pay debt with paper profits; it needs cold hard cash. So we always check how much of that EBIT is translated into free cash flow. Considering the last three years, Winning Health Technology Group actually recorded a cash outflow, overall. Debt is usually more expensive, and almost always more risky in the hands of a company with negative free cash flow. Shareholders ought to hope for an improvement.

但是我們最終的考慮因素也很重要,因爲公司無法用紙面利潤來償還債務;它需要冷硬現金。因此,我們總是檢查息稅前利潤中有多少轉化爲自由現金流。考慮到過去三年,Winning Health Technology Group實際上總體上記錄了現金流出。債務通常更昂貴,而且對於自由現金流爲負的公司來說,風險幾乎總是更大。股東們應該希望有所改善。

Our View

我們的觀點

Based on what we've seen Winning Health Technology Group is not finding it easy, given its conversion of EBIT to free cash flow, but the other factors we considered give us cause to be optimistic. There's no doubt that it has an adequate capacity to handle its total liabilities. It's also worth noting that Winning Health Technology Group is in the Healthcare Services industry, which is often considered to be quite defensive. When we consider all the factors mentioned above, we do feel a bit cautious about Winning Health Technology Group's use of debt. While we appreciate debt can enhance returns on equity, we'd suggest that shareholders keep close watch on its debt levels, lest they increase. The balance sheet is clearly the area to focus on when you are analysing debt. But ultimately, every company can contain risks that exist outside of the balance sheet. Case in point: We've spotted 2 warning signs for Winning Health Technology Group you should be aware of.

根據我們所見,鑑於Winning Health Technology Group將息稅前利潤轉換爲自由現金流,它並不容易,但是我們考慮的其他因素使我們有理由感到樂觀。毫無疑問,它有足夠的能力來處理其總負債。還值得注意的是,Winning Health Technology Group屬於醫療保健服務行業,該行業通常被認爲具有很強的防禦性。當我們考慮上述所有因素時,我們對Winning Health Technology Group的債務使用確實有些謹慎。儘管我們意識到債務可以提高股本回報率,但我們建議股東密切關注其債務水平,以免債務增加。資產負債表顯然是分析債務時需要關注的領域。但歸根結底,每家公司都可以控制資產負債表之外存在的風險。一個很好的例子:我們已經發現了Winning Health Technology Group的兩個警告信號,你應該注意。

When all is said and done, sometimes its easier to focus on companies that don't even need debt. Readers can access a list of growth stocks with zero net debt 100% free, right now.

當一切都說完之後,有時更容易將注意力集中在甚至不需要債務的公司身上。讀者現在可以免費訪問淨負債爲零的成長型股票清單。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St 的這篇文章本質上是籠統的。我們僅使用公正的方法提供基於歷史數據和分析師預測的評論,我們的文章並非旨在提供財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不會考慮最新的價格敏感型公司公告或定性材料。華爾街只是沒有持有上述任何股票的頭寸。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論